Jade Biosciences (JBIO) director receives 47,675 stock options at $21.81 strike

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Jade Biosciences, Inc. director Mark Eisner reported receiving a stock option grant that gives him the right to buy 47,675 shares of common stock at an exercise price of $21.81 per share. All 47,675 option shares were reported as held directly after the grant.

The option expires on June 24, 2036. According to the footnote, 1/36 of the total option shares vest monthly after the grant date, as long as Eisner continues to provide service to the company on each vesting date. This structure turns the award into ongoing, service-based compensation rather than an immediate, fully vested position.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Eisner Mark

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	47,675	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 47,675 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 47,675 options Exercise price: $21.81 per share Underlying shares: 47,675 shares +3 more

6 metrics

Option grant size 47,675 options Stock Option (Right to Buy) granted to director

Exercise price $21.81 per share Conversion or exercise price for common stock

Underlying shares 47,675 shares Common stock underlying the option grant

Post-grant derivative holdings 47,675 options Total derivative shares following transaction

Option expiration June 24, 2036 Expiration date of stock option grant

Vesting schedule 1/36 monthly Monthly vesting of total option shares

Key Terms

Stock Option (Right to Buy), exercise price, vest monthly, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 21.8100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest monthly financial

"1/36th of the total number of shares of common stock subject to the option vest monthly"

expiration date financial

"expiration_date: 2036-06-24T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 09:21 PM Accepted by SEC EDGAR 06/26/2026 - 09:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eisner Mark

(Last)

(First)

(Middle)

C/O JADE BIOSCIENCES, INC.

221 CRESCENT ST., BLDG. 23, STE. 105

(Street)

WALTHAM

MASSACHUSETTS

02453

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jade Biosciences, Inc. [ JBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$21.81	06/25/2026		A		47,675		⁽¹⁾	06/24/2036	Common Stock	47,675	$0	47,675	D

Explanation of Responses:

1. 1/36th of the total number of shares of common stock subject to the option vest monthly following the date of grant, subject to the Reporting Person's continued service to the Issuer through each vesting date.

	/s/ Elizabeth Balta, as attorney-in-fact for Mark Eisner	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Jade Biosciences (JBIO) director Mark Eisner report on this Form 4?

Mark Eisner reported a grant of stock options for 47,675 shares of Jade Biosciences common stock. These options were awarded at no cost, with an exercise price of $21.81 per share and are held directly as a compensation-related award.

What is the exercise price of Mark Eisner’s Jade Biosciences (JBIO) stock options?

The stock options granted to Mark Eisner have an exercise price of $21.81 per share. This means he can buy Jade Biosciences common stock at $21.81 once the options vest and before they expire on June 24, 2036.

How many Jade Biosciences (JBIO) shares are covered by Mark Eisner’s new option grant?

The option grant covers 47,675 shares of Jade Biosciences common stock. All 47,675 shares were reported as directly owned derivative securities following the transaction, reflecting the full size of the compensation award granted on the reported date.

When do Mark Eisner’s Jade Biosciences (JBIO) stock options vest?

The options vest in equal monthly installments, with 1/36 of the total 47,675 shares vesting each month after the grant date. Vesting continues only if Eisner remains in service to Jade Biosciences on each monthly vesting date, linking the award to ongoing service.

When do Mark Eisner’s Jade Biosciences (JBIO) stock options expire?

The stock options granted to Mark Eisner expire on June 24, 2036. He may exercise vested portions of the 47,675-share option grant at $21.81 per share any time before that expiration date, subject to the company’s equity plan and agreement terms.